Warburg Pincus Nears Deal for Specialty Pharmacy PantheRx Rare
The transaction for PantheRx Rare is valued at over $7 billion, according to a report.
Warburg Pincus is nearing an agreement to acquire specialty pharmacy company PantheRx Rare for more than $7 billion, The Wall Street Journal reported, citing people familiar with the matter. PantheRx Rare has been under the ownership of a group of private-equity firms since 2022.
Specialty pharmacies focus on dispensing high-cost, complex medications often used to treat chronic or rare diseases. These companies typically offer patient support services, such as adherence programs and financial assistance, alongside medication management.
The deal, if completed, would represent a significant transaction within the healthcare services sector, reflecting continued investor interest in companies that manage complex pharmaceutical treatments and patient care pathways.